{"id":33071,"date":"2025-05-09T12:47:06","date_gmt":"2025-05-09T04:47:06","guid":{"rendered":"https:\/\/flcube.com\/?p=33071"},"modified":"2025-08-26T13:57:21","modified_gmt":"2025-08-26T05:57:21","slug":"humanwell-healthcare-gains-nmpa-clearance-for-hz-j001-cream-in-vitiligo-trial","status":"publish","type":"post","link":"https:\/\/flcube.com\/?p=33071","title":{"rendered":"Humanwell Healthcare Gains NMPA Clearance for HZ-J001 Cream in Vitiligo Trial"},"content":{"rendered":"\n<p>China-based Humanwell Healthcare (Group) Co., Ltd (<a href=\"https:\/\/www.google.com\/finance\/quote\/600079:SHA\">SHA: 600079<\/a>) announced that it has received clearance from the National Medical Products Administration (NMPA) to conduct a multi-center, randomized, double-blinded, placebo-controlled Phase II study of its HZ-J001 cream. The study will evaluate the efficacy and safety of the cream in patients with non-segmental vitiligo.<\/p>\n\n\n\n<p><strong>Previous Approvals and Market Landscape<\/strong><br>HZ-J001 cream was previously approved for clinical studies in atopic dermatitis, alopecia areata, and vitiligo in China in October 2023. In the domestic market, there are two similar drugs for vitiligo at the Phase II stage, one at the Phase III stage, and another that has been filed for marketing.<a href=\"https:\/\/flcube.com\/\">-Fineline Info &amp; Tech<\/a><\/p>\n\n\n\n<div data-wp-interactive=\"core\/file\" class=\"wp-block-file\"><object data-wp-bind--hidden=\"!state.hasPdfPreview\" hidden class=\"wp-block-file__embed\" data=\"https:\/\/flcube.com\/wp-content\/uploads\/2025\/05\/600079_20250509_EUKP.pdf\" type=\"application\/pdf\" style=\"width:100%;height:600px\" aria-label=\"Embed of 600079_20250509_EUKP.\"><\/object><a id=\"wp-block-file--media-3cb2d8d1-6e10-401e-adf0-339818459e0f\" href=\"https:\/\/flcube.com\/wp-content\/uploads\/2025\/05\/600079_20250509_EUKP.pdf\">600079_20250509_EUKP<\/a><a href=\"https:\/\/flcube.com\/wp-content\/uploads\/2025\/05\/600079_20250509_EUKP.pdf\" class=\"wp-block-file__button wp-element-button\" download aria-describedby=\"wp-block-file--media-3cb2d8d1-6e10-401e-adf0-339818459e0f\">Download<\/a><\/div>\n","protected":false},"excerpt":{"rendered":"<p>China-based Humanwell Healthcare (Group) Co., Ltd (SHA: 600079) announced that it has received clearance from&#8230;<\/p>\n","protected":false},"author":1,"featured_media":33072,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"googlesitekit_rrm_CAownpewDA:productID":"","_jetpack_memberships_contains_paid_content":false,"footnotes":"","jetpack_publicize_message":"","jetpack_publicize_feature_enabled":true,"jetpack_social_post_already_shared":true,"jetpack_social_options":{"image_generator_settings":{"template":"highway","default_image_id":0,"font":"","enabled":false},"version":2}},"categories":[7,11],"tags":[62,266,1098],"class_list":["post-33071","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-company","category-drug","tag-clinical-trial-approval-initiation","tag-humanwell-healthcare","tag-sha-600079"],"yoast_head":"<!-- This site is optimized with the Yoast SEO Premium plugin v23.6 (Yoast SEO v27.5) - https:\/\/yoast.com\/product\/yoast-seo-premium-wordpress\/ -->\n<title>Humanwell Healthcare Gains NMPA Clearance for HZ-J001 Cream in Vitiligo Trial - Insight, China&#039;s Pharmaceutical Industry<\/title>\n<meta name=\"description\" content=\"China-based Humanwell Healthcare (Group) Co., Ltd (SHA: 600079) announced that it has received clearance from the National Medical Products Administration (NMPA) to conduct a multi-center, randomized, double-blinded, placebo-controlled Phase II study of its HZ-J001 cream. The study will evaluate the efficacy and safety of the cream in patients with non-segmental vitiligo.\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/flcube.com\/?p=33071\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Humanwell Healthcare Gains NMPA Clearance for HZ-J001 Cream in Vitiligo Trial\" \/>\n<meta property=\"og:description\" content=\"China-based Humanwell Healthcare (Group) Co., Ltd (SHA: 600079) announced that it has received clearance from the National Medical Products Administration (NMPA) to conduct a multi-center, randomized, double-blinded, placebo-controlled Phase II study of its HZ-J001 cream. The study will evaluate the efficacy and safety of the cream in patients with non-segmental vitiligo.\" \/>\n<meta property=\"og:url\" content=\"https:\/\/flcube.com\/?p=33071\" \/>\n<meta property=\"og:site_name\" content=\"Insight, China&#039;s Pharmaceutical Industry\" \/>\n<meta property=\"article:publisher\" content=\"https:\/\/www.facebook.com\/profile.php?id=61566606313834\" \/>\n<meta property=\"article:published_time\" content=\"2025-05-09T04:47:06+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2025-08-26T05:57:21+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/flcube.com\/wp-content\/uploads\/2025\/05\/0905.webp\" \/>\n\t<meta property=\"og:image:width\" content=\"1080\" \/>\n\t<meta property=\"og:image:height\" content=\"608\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/png\" \/>\n<meta name=\"author\" content=\"Fineline Cube\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:description\" content=\"Navigate the complexities of China\u2019s pharmaceutical industry with precision and clarity. FLCUBE delivers reliable data, news, and intelligence to broaden your horizons and sharpen your decision-making. Stay informed, stay ahead with FLCUBE.COM\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Fineline Cube\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"1 minute\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=33071#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=33071\"},\"author\":{\"name\":\"Fineline Cube\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/person\\\/19ad11870d326204db8524d3c3c5e66a\"},\"headline\":\"Humanwell Healthcare Gains NMPA Clearance for HZ-J001 Cream in Vitiligo Trial\",\"datePublished\":\"2025-05-09T04:47:06+00:00\",\"dateModified\":\"2025-08-26T05:57:21+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=33071\"},\"wordCount\":121,\"commentCount\":0,\"publisher\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"},\"image\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=33071#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2025\\\/05\\\/0905.webp\",\"keywords\":[\"Clinical trial approval \\\/ initiation\",\"Humanwell Healthcare\",\"SHA: 600079\"],\"articleSection\":[\"Company\",\"Drug\"],\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"CommentAction\",\"name\":\"Comment\",\"target\":[\"https:\\\/\\\/flcube.com\\\/?p=33071#respond\"]}],\"copyrightYear\":\"2025\",\"copyrightHolder\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"}},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=33071\",\"url\":\"https:\\\/\\\/flcube.com\\\/?p=33071\",\"name\":\"Humanwell Healthcare Gains NMPA Clearance for HZ-J001 Cream in Vitiligo Trial - Insight, China&#039;s Pharmaceutical Industry\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=33071#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=33071#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2025\\\/05\\\/0905.webp\",\"datePublished\":\"2025-05-09T04:47:06+00:00\",\"dateModified\":\"2025-08-26T05:57:21+00:00\",\"description\":\"China-based Humanwell Healthcare (Group) Co., Ltd (SHA: 600079) announced that it has received clearance from the National Medical Products Administration (NMPA) to conduct a multi-center, randomized, double-blinded, placebo-controlled Phase II study of its HZ-J001 cream. The study will evaluate the efficacy and safety of the cream in patients with non-segmental vitiligo.\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=33071#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/flcube.com\\\/?p=33071\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=33071#primaryimage\",\"url\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2025\\\/05\\\/0905.webp\",\"contentUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2025\\\/05\\\/0905.webp\",\"width\":1080,\"height\":608,\"caption\":\"Humanwell Healthcare Gains NMPA Clearance for HZ-J001 Cream in Vitiligo Trial\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=33071#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/flcube.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Humanwell Healthcare Gains NMPA Clearance for HZ-J001 Cream in Vitiligo Trial\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#website\",\"url\":\"https:\\\/\\\/flcube.com\\\/\",\"name\":\"Insight, China's Pharmaceutical Industry\",\"description\":\"Fineline Insights, Pharma Clarity\",\"publisher\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/flcube.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Organization\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\",\"name\":\"Fineline Infomation and Technology\",\"alternateName\":\"Fineline Info & Tech\",\"url\":\"https:\\\/\\\/flcube.com\\\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/logo\\\/image\\\/\",\"url\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/11\\\/Fineline-info-tech-scaled.jpg\",\"contentUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/11\\\/Fineline-info-tech-scaled.jpg\",\"width\":2560,\"height\":1894,\"caption\":\"Fineline Infomation and Technology\"},\"image\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/logo\\\/image\\\/\"},\"sameAs\":[\"https:\\\/\\\/www.facebook.com\\\/profile.php?id=61566606313834\"]},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/person\\\/19ad11870d326204db8524d3c3c5e66a\",\"name\":\"Fineline Cube\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"caption\":\"Fineline Cube\"},\"sameAs\":[\"https:\\\/\\\/flcube.com\"],\"url\":\"https:\\\/\\\/flcube.com\\\/?author=1\"}]}<\/script>\n<!-- \/ Yoast SEO Premium plugin. -->","yoast_head_json":{"title":"Humanwell Healthcare Gains NMPA Clearance for HZ-J001 Cream in Vitiligo Trial - Insight, China&#039;s Pharmaceutical Industry","description":"China-based Humanwell Healthcare (Group) Co., Ltd (SHA: 600079) announced that it has received clearance from the National Medical Products Administration (NMPA) to conduct a multi-center, randomized, double-blinded, placebo-controlled Phase II study of its HZ-J001 cream. The study will evaluate the efficacy and safety of the cream in patients with non-segmental vitiligo.","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/flcube.com\/?p=33071","og_locale":"en_US","og_type":"article","og_title":"Humanwell Healthcare Gains NMPA Clearance for HZ-J001 Cream in Vitiligo Trial","og_description":"China-based Humanwell Healthcare (Group) Co., Ltd (SHA: 600079) announced that it has received clearance from the National Medical Products Administration (NMPA) to conduct a multi-center, randomized, double-blinded, placebo-controlled Phase II study of its HZ-J001 cream. The study will evaluate the efficacy and safety of the cream in patients with non-segmental vitiligo.","og_url":"https:\/\/flcube.com\/?p=33071","og_site_name":"Insight, China&#039;s Pharmaceutical Industry","article_publisher":"https:\/\/www.facebook.com\/profile.php?id=61566606313834","article_published_time":"2025-05-09T04:47:06+00:00","article_modified_time":"2025-08-26T05:57:21+00:00","og_image":[{"width":1080,"height":608,"url":"https:\/\/flcube.com\/wp-content\/uploads\/2025\/05\/0905.webp","type":"image\/png"}],"author":"Fineline Cube","twitter_card":"summary_large_image","twitter_description":"Navigate the complexities of China\u2019s pharmaceutical industry with precision and clarity. FLCUBE delivers reliable data, news, and intelligence to broaden your horizons and sharpen your decision-making. Stay informed, stay ahead with FLCUBE.COM","twitter_misc":{"Written by":"Fineline Cube","Est. reading time":"1 minute"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/flcube.com\/?p=33071#article","isPartOf":{"@id":"https:\/\/flcube.com\/?p=33071"},"author":{"name":"Fineline Cube","@id":"https:\/\/flcube.com\/#\/schema\/person\/19ad11870d326204db8524d3c3c5e66a"},"headline":"Humanwell Healthcare Gains NMPA Clearance for HZ-J001 Cream in Vitiligo Trial","datePublished":"2025-05-09T04:47:06+00:00","dateModified":"2025-08-26T05:57:21+00:00","mainEntityOfPage":{"@id":"https:\/\/flcube.com\/?p=33071"},"wordCount":121,"commentCount":0,"publisher":{"@id":"https:\/\/flcube.com\/#organization"},"image":{"@id":"https:\/\/flcube.com\/?p=33071#primaryimage"},"thumbnailUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2025\/05\/0905.webp","keywords":["Clinical trial approval \/ initiation","Humanwell Healthcare","SHA: 600079"],"articleSection":["Company","Drug"],"inLanguage":"en-US","potentialAction":[{"@type":"CommentAction","name":"Comment","target":["https:\/\/flcube.com\/?p=33071#respond"]}],"copyrightYear":"2025","copyrightHolder":{"@id":"https:\/\/flcube.com\/#organization"}},{"@type":"WebPage","@id":"https:\/\/flcube.com\/?p=33071","url":"https:\/\/flcube.com\/?p=33071","name":"Humanwell Healthcare Gains NMPA Clearance for HZ-J001 Cream in Vitiligo Trial - Insight, China&#039;s Pharmaceutical Industry","isPartOf":{"@id":"https:\/\/flcube.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/flcube.com\/?p=33071#primaryimage"},"image":{"@id":"https:\/\/flcube.com\/?p=33071#primaryimage"},"thumbnailUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2025\/05\/0905.webp","datePublished":"2025-05-09T04:47:06+00:00","dateModified":"2025-08-26T05:57:21+00:00","description":"China-based Humanwell Healthcare (Group) Co., Ltd (SHA: 600079) announced that it has received clearance from the National Medical Products Administration (NMPA) to conduct a multi-center, randomized, double-blinded, placebo-controlled Phase II study of its HZ-J001 cream. The study will evaluate the efficacy and safety of the cream in patients with non-segmental vitiligo.","breadcrumb":{"@id":"https:\/\/flcube.com\/?p=33071#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/flcube.com\/?p=33071"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/flcube.com\/?p=33071#primaryimage","url":"https:\/\/flcube.com\/wp-content\/uploads\/2025\/05\/0905.webp","contentUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2025\/05\/0905.webp","width":1080,"height":608,"caption":"Humanwell Healthcare Gains NMPA Clearance for HZ-J001 Cream in Vitiligo Trial"},{"@type":"BreadcrumbList","@id":"https:\/\/flcube.com\/?p=33071#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/flcube.com\/"},{"@type":"ListItem","position":2,"name":"Humanwell Healthcare Gains NMPA Clearance for HZ-J001 Cream in Vitiligo Trial"}]},{"@type":"WebSite","@id":"https:\/\/flcube.com\/#website","url":"https:\/\/flcube.com\/","name":"Insight, China's Pharmaceutical Industry","description":"Fineline Insights, Pharma Clarity","publisher":{"@id":"https:\/\/flcube.com\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/flcube.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Organization","@id":"https:\/\/flcube.com\/#organization","name":"Fineline Infomation and Technology","alternateName":"Fineline Info & Tech","url":"https:\/\/flcube.com\/","logo":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/flcube.com\/#\/schema\/logo\/image\/","url":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","contentUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","width":2560,"height":1894,"caption":"Fineline Infomation and Technology"},"image":{"@id":"https:\/\/flcube.com\/#\/schema\/logo\/image\/"},"sameAs":["https:\/\/www.facebook.com\/profile.php?id=61566606313834"]},{"@type":"Person","@id":"https:\/\/flcube.com\/#\/schema\/person\/19ad11870d326204db8524d3c3c5e66a","name":"Fineline Cube","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","caption":"Fineline Cube"},"sameAs":["https:\/\/flcube.com"],"url":"https:\/\/flcube.com\/?author=1"}]}},"jetpack_publicize_connections":[],"jetpack_featured_media_url":"https:\/\/flcube.com\/wp-content\/uploads\/2025\/05\/0905.webp","jetpack_sharing_enabled":true,"_links":{"self":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/33071","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcomments&post=33071"}],"version-history":[{"count":2,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/33071\/revisions"}],"predecessor-version":[{"id":33076,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/33071\/revisions\/33076"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/media\/33072"}],"wp:attachment":[{"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fmedia&parent=33071"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcategories&post=33071"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Ftags&post=33071"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}